Liver impairment drug study completed: how golcadomide behaves
NCT ID NCT06535399
First seen Nov 12, 2025 · Last updated Jun 23, 2026 · Updated 35 times
Summary
This completed Phase 1 study looked at how the drug golcadomide is processed in the body of people with moderate or severe liver impairment compared to healthy volunteers. 29 adults received a single dose, and researchers measured drug levels and safety. The goal is to understand if liver problems change how the drug works, which could guide future dosing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Local Institution - 0001
Chandler, Arizona, 85225, United States
-
Local Institution - 0002
Orlando, Florida, 32809, United States
-
Texas Liver Institute
San Antonio, Texas, 78215, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
golcadomide (BMS-986369)
What this could lead to
If successful, this study could help determine safe dosing of golcadomide for people with liver problems.
What could go wrong
This is a very early (Phase 1) study with only 29 participants, so results may not apply broadly. The drug may still have safety issues or not work as expected.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.